ReviewAAPS PharmSciTech2026
Smart Stings of Nature: Harnessing Microneedles Assisted Targeted Phytoconstituent Delivery for Dermatological Disorders.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Needle gauge and length effects on human stem cell viability during injection: a comprehensive review.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microneedle-mediated transdermal delivery of phytoconstituents represents a sophisticated and emerging paradigm in dermatological therapeutics, bridging the pharmacological efficacy of plant-derived bioactive with the precision of advanced biomedical engineering. Conventional topical dosage forms are often constrained by the formidable barrier function of the stratum corneum, instability of phytochemicals, and suboptimal patient adherence. Microneedle arrays circumvent these limitations by creating transient microchannels that enable minimally invasive, painless, and controlled delivery of therapeutics into the viable epidermal and dermal layers. The bioactive compounds such as curcumin, resveratrol, asiaticoside, and glycyrrhizin exhibit multifaceted pharmacological activities, including anti-inflammatory, antioxidant, antimicrobial, and pro-regenerative effects, which are beneficial for the management of cutaneous pathologies such as psoriasis, eczema, acne vulgaris, and chronic ulcerations. The incorporation of these phytoconstituents into dissolving or hydrogel-forming microneedles enhances their physicochemical stability, facilitates sustained and localized drug release, and minimizes systemic exposure, thereby improving therapeutic efficacy and safety. The utilization of natural, biodegradable, and biocompatible polymers such as chitosan, hyaluronic acid, silk fibroin, and alginate, further augments the structural integrity and bioperformance of microneedle systems while aligning with eco-sustainable pharmaceutical design principles. This integrative strategy signifies a pivotal advancement toward personalized dermatological interventions, enabling precise dosing and targeted pharmacokinetics. The future research should emphasize material innovation, in vivo pharmacodynamic assessment, and large-scale translational studies to validate the clinical potential of phytoconstituent-loaded microneedles as next-generation bioresponsive platforms for skin therapeutics.
Indexed as
Identifiers
41507645What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.